mAbs Against HUMAN Protein
LMO2
| STATUS: |  |
|---|---|
| CONTACT INFORMATION: | Monoclonal Antibodies Unit, Centro Nacional de Investigaciones Oncológicas |
| STATUS: | Validated |
| TYPE: | mouse anti human |
| CLONE NAME: | 1A9-1 |
| PROTEIN: | human full length LMO2 |
| PROTEIN WEB: | http://www.ncbi.nlm.nih.gov/protein/214832074 |
| ANTIGEN USED: | GST-LMO2 |
| FUSION PARTNER: | K6H6B5 |
| ISOTYPE: | IgG1 |
| SPECIES REACTIVITY: | human |
| PREPARATION AND STORAGE: | Aliquot and store at 4C. Do not freeze. |
| APP RECOMMENDED: | IHQ-paraffin, WB, IF |
| APP NO TESTED: | IHQ-frozen, IP, Flow cytometry |
Description
LMO2 encodes a cysteine-rich, two LIM-domain protein that is required for yolk sac erythropoiesis. The LMO2 protein has a central and crucial role in hematopoietic development and is highly conserved. The LMO2 transcription start site is located approximately 25 kb downstream from the 11p13 T-cell translocation cluster (11p13 ttc), where a number T-cell acute lymphoblastic leukemia-specific translocations occur. Alternative splicing results in multiple transcript variants encoding different isoforms. LMO2 protein is expressed as a nuclear marker in normal germinal-center (GC) B cells and GC-derived B-cell lines and in a subset of GC-derived B-cell lymphomas. LMO2 is expressed in erythroid and myeloid precursors and in megakaryocytes and also in lymphoblastic and acute myeloid leukemias. It is rarely expressed in mature T, natural killer (NK), and plasma cell neoplasms and is absent from nonhematolymphoid tissues except for endothelial cells.
Publication describing antibody characterization/validation
Yasodha Natkunam, Shuchun Zhao, David Y. Mason, Jun Chen, Behnaz Taidi, Margaret Jones, Anne S. Hammer, Stephen Hamilton Dutoit, Izidore S. Lossos and Ronald Levy. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. 2007 109: 1636-1642.
Applications
| IHC Techniques | Clone | Dilution | Antibody concentration | Antigen retrieval method | Visualization kit | +/- control | Protein localization | Positivity in other species | Protocol |
|---|---|---|---|---|---|---|---|---|---|
| Frozen tissue and cytospins | |||||||||
| Paraffin tissue | |||||||||
Recommended Result obtained is satisfactory. The reagent can be use in this application | 1A9-1 | 1:4 | Tris-EDTA | Leica Bond Max | Tonsil / | ||||
| Immunofluorescence | |||||||||
Recommended Result obtained is satisfactory. The reagent can be use in this application | 1A9-1 | 1:100 | supernatant | Tonsil / | Available | ||||
Enlarge image
- LMO2 antibody (1A9-1) in transfected cells
- Cytoplasmic staining of LMO2 mAb in transfected HEK-V5-LMO2 cells. Anti-V5 mAb was used as positive control.
Enlarge image
- Anti-LMO2 in tonsil paraffin sections
Enlarge image
- LMO2 (1A9-1) immunofluorescence in human paraffin tonsil.
- Anti-LMO2 (1A9-1) is represented in red. DAPI in blue.
| WB Techniques | Clone | Dilution | Antibody concentration | +/- control | Expected MW | Observed Mw | Positivity in other species | Protocol |
|---|---|---|---|---|---|---|---|---|
| Western Blotting | ||||||||
Recommended Result obtained is satisfactory. The reagent can be use in this application | 1A9-1 | Neat | Supernatant | Ramos cell line / Hela cell line | 18kDa | 18kDa | Available | |
| Immunoprecipitation | ||||||||
Enlarge image
- Anti-LMO2 in western blotting technique
- Tubulin was used as loading control.
Lane 1 Transfected Hek-pcdna3-V5-LMO2 (20ug) (+)
Lane 2 Transfected Hek-pcdna3-V5-Bcl10 (20ug) (-)
Lane 3 SUDHL6 cell line (200ug) (+)
Lane 4 Ocil19 cell line (200ug) (+)
Lane 5 Ocily3 cell line (200ug) (-)
Lane 6 Raji cell line (200ug) (-)
Lane 7 Ramos cell line (200ug) (+)
Lane 8 HeLa cell line (200ug) (-)